Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators

Henrik Sunden; Mareike C. Holland; Pekka K. Poutiainen; Tiina Jaaskelainen; Juha T. Pulkkinen; Jorma J. Palvimo; Roger Olsson

doi:10.1021/jm501995n

Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators

Henrik Sunden, Mareike C. Holland, Pekka K. Poutiainen, Tiina Jaaskelainen, Juha T. Pulkkinen, Jorma J. Palvimo, Roger Olsson

Research output: Contribution to journal › Article › peer-review

Abstract

To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants.

Original language	English
Pages (from-to)	1569-1574
Journal	Journal of Medicinal Chemistry
Volume	58
Issue number	3
DOIs	https://doi.org/10.1021/jm501995n
Publication status	Published - 2015

Subject classification (UKÄ)

Medicinal Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/jm501995n

Cite this

@article{1f28a95d99774d08a04a60b50d088b85,

title = "Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators",

abstract = "To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants.",

author = "Henrik Sunden and Holland, {Mareike C.} and Poutiainen, {Pekka K.} and Tiina Jaaskelainen and Pulkkinen, {Juha T.} and Palvimo, {Jorma J.} and Roger Olsson",

year = "2015",

doi = "10.1021/jm501995n",

language = "English",

volume = "58",

pages = "1569--1574",

journal = "Journal of Medicinal Chemistry",

issn = "1520-4804",

publisher = "The American Chemical Society (ACS)",

number = "3",

}

TY - JOUR

T1 - Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators

AU - Sunden, Henrik

AU - Holland, Mareike C.

AU - Poutiainen, Pekka K.

AU - Jaaskelainen, Tiina

AU - Pulkkinen, Juha T.

AU - Palvimo, Jorma J.

AU - Olsson, Roger

PY - 2015

Y1 - 2015

N2 - To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants.

AB - To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants.

U2 - 10.1021/jm501995n

DO - 10.1021/jm501995n

M3 - Article

C2 - 25646649

SN - 1520-4804

VL - 58

SP - 1569

EP - 1574

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 3

ER -

Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this